# Global Surgical Intelligence Network (GSIN)
## Architecture and Implementation Guide — P23

---

## 1. Vision and Scope

### What the GSIN Is

The Global Surgical Intelligence Network (GSIN) is a secure, anonymized cross-network intelligence platform enabling hospitals, vendor organizations, manufacturers, and national regulatory bodies to collaborate around surgical instrument quality, contamination detection, baseline governance, predictive analytics, and surgical safety.

The GSIN aggregates anonymized quality signals across participating tenants, applies differential privacy and k-anonymity controls, and publishes de-identified intelligence that no single participant could generate alone. It creates a collective intelligence layer on top of individual tenant quality programs.

### What the GSIN Is NOT

- **Not a patient data network.** No patient identifiers, clinical records, or health outcomes are collected, processed, or transmitted. Patient data never enters the GSIN.
- **Not a clinical decision system.** GSIN outputs do not constitute clinical recommendations. All outputs require human clinical and quality review before action.
- **Not a regulatory body.** The GSIN does not issue regulatory recalls, safety notices, or compliance determinations. It generates early warning signals for human review and regulatory consultation.
- **Not a real-time operational system.** Signals are published after governance review, not in real time.
- **Not a causation engine.** GSIN outputs identify associations in aggregate anonymized data. They do not establish, imply, or claim causation.

### Participant Types

| Type | Role | Data Access | Contribution |
|------|------|-------------|--------------|
| Hospital | Primary contributor and consumer | Regional + global signals | Inspection metrics, quality rates, contamination patterns |
| Vendor Organization | Contributor and consumer | Category-specific signals | Quality rates, CAPA patterns |
| Manufacturer | Contributor (limited) and consumer | Category-specific signals relevant to their products | Quality performance data |
| National Regulatory Body | Observer only | Aggregate evidence packages | None — read-only access |

---

## 2. Architecture Overview

### Data Flow

```
[Hospital A — Tenant] ──┐
[Hospital B — Tenant] ──┤
[Hospital C — Tenant] ──┼──► [Anonymization Layer] ──► [Global Intelligence Core] ──► [Participant Dashboards]
[Vendor Org — Tenant]  ──┤                                      │
[Manufacturer — Tenant]──┘                              [Regulatory Evidence Archive]
                                                                 │
                                                    [Regulatory Bodies — Read Only]
                                                    (FDA / Health Canada / EU MDR /
                                                     TGA / PMDA / MFDS)
```

### Component Architecture

```
┌─────────────────────────────────────────────────────────────┐
│                    Tenant Boundary                          │
│  ┌──────────────┐  ┌──────────────┐  ┌──────────────────┐  │
│  │  Inspection  │  │  CAPA Engine │  │  Quality Metrics │  │
│  │   Records    │  │              │  │   Dashboard      │  │
│  └──────┬───────┘  └──────┬───────┘  └────────┬─────────┘  │
│         │                 │                    │            │
│         └─────────────────┴────────────────────┘            │
│                           │                                 │
│                    ┌──────▼──────┐                          │
│                    │  Signal     │                          │
│                    │  Extractor  │                          │
│                    └──────┬──────┘                          │
└───────────────────────────┼─────────────────────────────────┘
                            │  Anonymized aggregate only
                            ▼
┌─────────────────────────────────────────────────────────────┐
│                 Anonymization Layer                         │
│  • k-anonymity verification (k≥10)                         │
│  • Differential privacy (Laplace noise ε=0.05)             │
│  • Facility pseudonymization (SHA-256 + monthly salt)      │
│  • Category generalization                                  │
└──────────────────────┬──────────────────────────────────────┘
                       │
                       ▼
┌─────────────────────────────────────────────────────────────┐
│              Global Intelligence Core                       │
│  ┌──────────────┐  ┌──────────────┐  ┌──────────────────┐  │
│  │  Signal      │  │  Recall      │  │  Risk Registry   │  │
│  │  Publisher   │  │  Early       │  │  Engine          │  │
│  │              │  │  Warning     │  │                  │  │
│  └──────────────┘  └──────────────┘  └──────────────────┘  │
│  ┌──────────────┐  ┌──────────────┐  ┌──────────────────┐  │
│  │  Predictive  │  │  Regulatory  │  │  Governance      │  │
│  │  Analytics   │  │  Evidence    │  │  Review Gate     │  │
│  │  Engine      │  │  Archive     │  │                  │  │
│  └──────────────┘  └──────────────┘  └──────────────────┘  │
└─────────────────────────────────────────────────────────────┘
```

---

## 3. Seven Focus Areas

### 3.1 Global Benchmarking

**Description:** Anonymized instrument quality rates by category, region, and facility type, enabling participating facilities to understand their quality performance relative to the network.

**Data Inputs:**
- Inspection pass/fail rates by instrument category
- Contamination finding rates
- Decontamination cycle compliance metrics
- CAPA completion rates

**Outputs:**
- Regional quality benchmarks by instrument category
- Percentile rankings (anonymized)
- Trend comparisons against network baseline

**Privacy Controls:**
- k≥10 facilities required before any benchmark published
- Facility-level data aggregated; no individual facility rate disclosed
- Differential privacy noise applied to rate estimates

**Governance Constraints:**
- Benchmarks reviewed by GSIN Governance Board quarterly
- Facility type generalization applied (academic medical center / community hospital / ambulatory surgery center)
- No geographic precision below regional level

---

### 3.2 Instrument Risk Registry

**Description:** Cross-network instrument failure and contamination pattern registry, enabling early identification of risk patterns associated with specific instrument categories.

**Data Inputs:**
- Finding type by instrument category
- Risk scores from tenant-level analysis
- Facilities reporting count per pattern

**Outputs:**
- Risk registry entries by instrument category and pattern type
- Registry status: monitoring / elevated / active_signal / resolved
- Trend direction per category

**Privacy Controls:**
- Minimum 5 facilities reporting required for registry inclusion
- Manufacturer identification generalized to tier/category level
- No facility-specific data in registry entries

**Governance Constraints:**
- Registry entries require human review before publication
- Elevated and active_signal entries trigger governance notification
- Resolved entries archived and not removed

---

### 3.3 Recall Signal Detection

**Description:** Early warning system detecting when N≥5 facilities report the same (instrument category, finding type) pattern within a rolling 90-day window.

**Data Inputs:**
- Facility-level finding type counts by instrument category
- Rolling 90-day aggregation
- Signal strength scoring

**Outputs:**
- Early warning signals at active / under_review / escalated / resolved status
- Manufacturer notification status
- Regulatory notification status

**Privacy Controls:**
- Facility count disclosed as aggregate integer only
- No facility pseudonyms or ordering disclosed in warning signals
- Signal content reviewed for re-identification risk before publication

**Governance Constraints:**
- All recall early warnings require human review before distribution
- Escalated warnings trigger Governance Board emergency review
- Warning signals are NOT regulatory recall notices

---

### 3.4 Anonymized Learning Network

**Description:** Federated quality learning framework enabling cross-network pattern recognition without raw data leaving tenant boundaries.

**Data Inputs:**
- Aggregated quality metrics computed within tenant boundary
- Pattern vectors (not raw records)
- CAPA effectiveness signals

**Outputs:**
- Network-wide quality improvement signals
- Predictive risk factors
- Intervention effectiveness benchmarks

**Privacy Controls:**
- No raw instrument images leave tenant boundary
- No patient data in any network signal
- Pattern vectors designed to prevent reverse-engineering of individual records

**Governance Constraints:**
- Federated learning model updates reviewed by Privacy Officer
- Model governance documented and audited annually

---

### 3.5 Regulatory Evidence Exchange

**Description:** Structured evidence packages for regulatory submissions, providing aggregated de-identified quality evidence to regulatory authorities.

**Data Inputs:**
- Aggregated quality performance metrics
- Recall signal data
- Safety pattern summaries
- Benchmarking data

**Outputs:**
- Evidence packages by target authority (FDA / Health Canada / EU MDR / TGA / PMDA / MFDS)
- Cryptographically signed and timestamped packages
- Read-only access for regulatory observers

**Privacy Controls:**
- k≥10 facility minimum for any evidence package
- No facility-identifiable data in packages
- Evidence packages contain aggregates only

**Governance Constraints:**
- All evidence packages require human review before publication
- Packages do not constitute regulatory clearance or approval
- Regulatory observers cannot query tenant-level data

---

### 3.6 Cross-System Predictive Analytics

**Description:** Network-wide trend forecasting, identifying emerging quality patterns before they reach critical thresholds.

**Data Inputs:**
- Historical network quality signals
- Instrument lifecycle data (anonymized)
- Seasonal pattern analysis
- CAPA intervention effectiveness

**Outputs:**
- 30/60/90-day quality trend forecasts by region and category
- Risk factor identification
- Intervention recommendation signals

**Privacy Controls:**
- Forecasts are aggregate-only; no facility-level predictions disclosed
- Confidence intervals applied; point predictions not presented as certain

**Governance Constraints:**
- Predictive outputs carry human_review_required=True
- Causation language explicitly prohibited in all predictive outputs
- Forecasts for awareness only; not for clinical or operational decisions without human review

---

### 3.7 Global Surgical Quality Dashboards

**Description:** Role and region-specific intelligence dashboards providing participating facilities with relevant network intelligence.

**Data Inputs:**
- Published global signals
- Risk registry entries
- Recall early warnings
- Participant contribution status
- Regulatory evidence packages

**Outputs:**
- Consolidated dashboard by participant type and region
- KPI summary: active signals, recall warnings, registry entries, network participants
- Contribution status and reciprocity metrics

**Privacy Controls:**
- Dashboards show only published, k-anonymity-verified signals
- No facility-level data surfaced in shared dashboards

**Governance Constraints:**
- Dashboard content subject to Governance Board approval
- All outputs carry disclaimer and human_review_required flag

---

## 4. Privacy Architecture

### k-Anonymity

The GSIN applies k-anonymity with k≥10 for global network signals, stricter than the P15 domestic network threshold of k≥5. No signal is published unless at least 10 distinct participating facilities contribute to the aggregate. Signals with fewer than 10 contributing facilities are held in monitoring status pending additional contributions.

### Differential Privacy

Laplace mechanism noise is applied with privacy budget ε=0.05, stricter than the P15 domestic threshold of ε=0.1. This ensures that the addition or removal of any single facility's data does not materially alter published signals, protecting each participant's contribution from inference.

### Facility Pseudonymization

Facility identifiers are pseudonymized using SHA-256(facility_id + global_monthly_salt) where the salt rotates monthly. This prevents cross-month linkage of facility contributions while maintaining within-month audit integrity. Pseudonymized facility IDs are used only in internal audit logs; they are never published in network signals.

### Data Boundary Controls

- No raw instrument images leave tenant boundary at any time.
- No patient data enters the GSIN pipeline at any stage.
- Cross-border data transfers comply with GDPR adequacy decisions, Standard Contractual Clauses (SCCs), and jurisdiction-specific data transfer requirements.

### Cross-Border Transfer Controls

| Region Pair | Control Mechanism |
|-------------|------------------|
| US → EU | SCCs (controller-to-processor) |
| US → UK | UK SCCs (IDTA) |
| US → Australia | OAIC Privacy Act compliance |
| EU → non-EU | GDPR adequacy or SCCs |
| Any → Japan | APPI cross-border transfer controls |

---

## 5. Data Sharing Model

### Opt-In Per Category

Facility participation in the GSIN is opt-in. Participants configure which data categories they contribute:

| Contribution Type | Description |
|------------------|-------------|
| inspection_metrics | Aggregate inspection pass/fail rates |
| quality_rates | Quality performance rates by instrument category |
| recall_signals | Patterns contributing to recall early warning detection |
| baseline_deviations | Deviations from established baseline quality rates |
| capa_patterns | CAPA completion and effectiveness patterns |

### Minimum Contribution Threshold

To qualify for network benchmarks, participants must contribute within a 90-day rolling window with a minimum of 100 inspections per month. Participants below this threshold are excluded from benchmark comparisons until the threshold is met.

### Reciprocity Model

Contributors receive richer intelligence than non-contributors:

| Tier | Contribution Level | Intelligence Access |
|------|--------------------|---------------------|
| Observer | No contribution | Public network stats only |
| Basic | 1–2 categories, <100/month | Regional signals |
| Standard | 3+ categories, ≥100/month | Regional + category-specific signals |
| Full | All categories, ≥500/month | Full global intelligence + early warnings |

---

## 6. Security Model

### Encryption

- End-to-end encryption on all inter-tenant signal transmissions (TLS 1.3 minimum).
- Data at rest encrypted using AES-256.
- Evidence packages cryptographically signed (SHA-256 hash with private key signing).

### Regional Data Planes

Regional data planes ensure that no PHI or facility-identifiable data crosses regional boundaries. Anonymized aggregates flow through regional aggregation nodes before entering the Global Intelligence Core.

### Audit Logging

Every signal contribution and intelligence query is logged with:
- Timestamp
- Tenant identifier
- Action type
- Resource type
- Actor identifier
- Correlation ID

### Authentication

| Access Type | Authentication Mechanism |
|-------------|--------------------------|
| System-to-system | mTLS (mutual TLS) |
| User access (dashboard) | OAuth 2.0 with JWT |
| Regulatory observer access | OAuth 2.0 with read-only scope |

### Penetration Testing

Global network endpoints are included in the annual penetration testing scope. Findings are remediated within 30 days (critical), 60 days (high), and 90 days (medium). Penetration test reports are available to Governance Board members.

---

## 7. Governance Model

### GSIN Governance Board

Composition:
- 3 hospital representatives (elected by hospital participants annually)
- 2 vendor organization representatives (elected by vendor participants annually)
- 1 independent clinical advisor (appointed by Governance Board, 2-year term)
- 1 privacy officer (appointed by Governance Board, 2-year term)
- 1 technical security representative (appointed by Governance Board, 2-year term)

Voting: Simple majority for routine decisions; 2/3 supermajority for signal publication policy changes and participant suspension.

### Signal Publication Standards

Before any global signal is published to the network:
1. k-anonymity verified: facility_count ≥ 10
2. Differential privacy noise applied
3. Human review completed by at least one Governance Board member
4. Disclaimer and association_reason attached
5. Causation language reviewed and removed

### Privacy Review Process

The Privacy Officer reviews all signal types and evidence packages quarterly. Any signal type introducing new data categories requires Privacy Officer approval before deployment.

### Participant Onboarding

Requirements before network participation:
- Business Associate Agreement (BAA) signed (US participants)
- Data Processing Agreement (DPA) signed (EU and UK participants)
- Security attestation: annual SOC 2 Type II or equivalent
- Technical integration: validated GSIN API integration test
- Governance training: GSIN data governance training completed

### Appeal Mechanism

Participants may dispute signals affecting their product/facility category:
1. Submit written dispute to Governance Board with supporting evidence
2. Governance Board reviews within 30 days
3. Signal placed under_review status during dispute period
4. Board issues written determination; majority vote required

---

## 8. Regulatory Evidence Exchange

### Architecture

The Regulatory Evidence Exchange is a read-only archive of de-identified, aggregated quality evidence for regulatory submissions. Regulatory authorities access evidence packages through a dedicated read-only API scope.

### Supported Authorities

| Authority | Jurisdiction | Evidence Framework |
|-----------|-------------|-------------------|
| FDA | United States | Quality System Regulation (QSR), 21 CFR Part 820 |
| Health Canada | Canada | Medical Devices Regulations, SOR/98-282 |
| EU MDR | European Union | EU MDR 2017/745, Article 83 post-market surveillance |
| TGA | Australia | Therapeutic Goods Act 1989, post-market surveillance |
| PMDA | Japan | Pharmaceutical and Medical Device Act |
| MFDS | South Korea | Medical Device Act |

### Package Integrity

Evidence packages are:
- Timestamped at creation and publication
- SHA-256 hashed for content integrity
- Signed using the GSIN evidence signing key

### Access Controls

- Regulatory observers have read-only access to published evidence packages
- No regulatory observer can access tenant-level data
- Evidence packages contain anonymized aggregates only
- All evidence package access is audit-logged

---

## 9. Global Deployment Strategy

### Phase 1 — North America Pilot (0–12 months)

- 10 hospitals (5 academic medical centers, 5 community hospitals)
- 3 vendor organizations
- Region: United States and Canada
- Regulatory engagement: FDA pre-submission meeting; Health Canada stakeholder engagement
- Compliance: HIPAA BAA, PIPEDA/C-25

### Phase 2 — UK + Australia (12–24 months)

- UK: 5 NHS Trusts, 2 independent hospital groups
- Australia: 5 public hospitals, 2 private hospital groups
- Regulatory sandbox: TGA pilot evidence exchange; MHRA stakeholder engagement
- Compliance: UK GDPR, Australian Privacy Act 1988

### Phase 3 — EU + Singapore (24–36 months)

- EU: 10 hospitals across Germany, France, Netherlands
- Singapore: 3 public health institutions (MOH Holdings)
- GDPR full compliance: DPA agreements, data residency in EU
- HSA (Singapore) engagement for ASEAN expansion planning

### Phase 4 — Japan + South Korea (36–48 months)

- Japan: 5 hospital systems, PMDA engagement
- South Korea: 3 hospital groups, MFDS engagement
- Localization: Japanese and Korean language support
- APPI (Japan) cross-border transfer compliance
- South Korea PIPA compliance

---

## 10. Adoption Roadmap

### Milestone Gates

| Milestone | Criteria |
|-----------|----------|
| Phase 1 Launch | 10 hospitals active, 3 signals published, governance board constituted |
| Phase 1 Complete | 100 inspections/month average across participants, 1 evidence package submitted |
| Phase 2 Launch | Legal framework complete for UK/AU, 5 participants onboarded |
| Phase 3 Launch | GDPR DPA templates approved, EU data plane operational |
| Phase 4 Launch | APPI transfer controls validated, Japanese localization complete |

### Participant Incentives

- Early adopter recognition in GSIN annual report
- Priority access to new intelligence features
- Reciprocal intelligence access tier upgrades
- Participation credit toward regulatory evidence package inclusion

### Governance Maturity Model

| Level | Description |
|-------|-------------|
| Level 1 | Governance Board constituted; signal publication policy adopted |
| Level 2 | Privacy review cycle operational; dispute mechanism tested |
| Level 3 | Annual penetration test completed; regulatory engagement active |
| Level 4 | International expansion governance framework operational |
| Level 5 | GSIN governance recognized by regulatory authorities as evidence standard |
